2Semana·

Iradimed Q3/26 Earnings

A niche player $IRMD (-1,34 %) in the healthcare sector; strong quarter, but management has slightly lowered its guidance. If the stock price drops a bit more, the valuation could become attractive again...

attachment
3
2 Comentarios

Imagen de perfil
Definitely an underrated player 👍
•
2
•
Imagen de perfil
@Aktienhauptmeister It certainly looks interesting, especially since they operate debt-free. But the valuation is still quite high.
••
Únase a la conversación